Categories

Tag: cancer therapy

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

Laminar Pharma Shares First PFS Data for LAM561 in Glioblastoma Treatment

March 5, 2025

Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced optimistic results from its ongoing clinical trial evaluating

Alpha Tau Receives Medical Device Single Audit Program Certification

Alpha Tau Receives Medical Device Single Audit Program Certification

February 25, 2025

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced the achievement of Medical Device Single Audit Program (MDSAP) certification

Share With

Recent Posts

Cleveland Clinic Expands Cancer Concierge for Faster Care

Walmart, Soda Health Launch AI-Powered Wellness Program

Consumers Divided on Health Insurers as Partner or Payer

HRT Club, Posterity Health Partner for Inclusive Hormone Care

How Account-Based Marketing Is Redefining Engagement in Healthcare

Fuel up with free Health Tech Insights